Total Payments
$2,912
2024 Payments
$298.86
Companies
16
Transactions
65
Medicare Patients
5,899
Medicare Billing
$384,264
Payment Breakdown by Category
Food & Beverage$2,762 (94.8%)
Other$150.00 (5.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,762 | 64 | 94.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $150.00 | 1 | 5.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bausch & Lomb, a division of Bausch Health US, LLC | $753.20 | 9 | $0 (2021) |
| Allergan, Inc. | $495.53 | 11 | $0 (2021) |
| Valeant Pharmaceuticals North America LLC | $409.13 | 7 | $0 (2017) |
| Aerie Pharmaceuticals, Inc. | $238.94 | 2 | $0 (2019) |
| Shire North American Group Inc | $208.03 | 6 | $0 (2018) |
| ABBVIE INC. | $167.74 | 5 | $0 (2024) |
| Kala Pharmaceuticals, Inc. | $139.14 | 8 | $0 (2021) |
| Bausch & Lomb Americas Inc. | $134.82 | 3 | $0 (2024) |
| RxSight Inc | $116.97 | 1 | $0 (2024) |
| TissueTech, Inc. | $77.24 | 4 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $298.86 | 6 | RxSight Inc ($116.97) |
| 2023 | $93.44 | 5 | Novartis Pharmaceuticals Corporation ($21.41) |
| 2022 | $134.94 | 3 | ABBVIE INC. ($134.94) |
| 2021 | $204.88 | 7 | Bausch & Lomb, a division of Bausch Health US, LLC ($101.87) |
| 2020 | $126.43 | 7 | Allergan, Inc. ($56.09) |
| 2019 | $624.60 | 13 | Bausch & Lomb, a division of Bausch Health US, LLC ($358.09) |
| 2018 | $704.63 | 12 | Bausch & Lomb, a division of Bausch Health US, LLC ($293.24) |
| 2017 | $724.52 | 12 | Valeant Pharmaceuticals North America LLC ($409.13) |
All Payment Transactions
65 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/07/2024 | ABBVIE INC. | LUMIGAN (Drug) | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: EYE CARE | ||||||
| 05/27/2024 | BIOTISSUE HOLDINGS INC. | — | Food and Beverage | In-kind items and services | $34.31 | General |
| 05/21/2024 | Bausch & Lomb Americas Inc. | XIIDRA (Drug) | Food and Beverage | In-kind items and services | $16.88 | General |
| Category: Ophthalmology | ||||||
| 05/16/2024 | Amgen Inc. | TEPEZZA (Biological) | Food and Beverage | In-kind items and services | $13.83 | General |
| Category: Inflammation/Rare Disease | ||||||
| 05/09/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Food and Beverage | In-kind items and services | $98.81 | General |
| Category: Ophthalmology | ||||||
| 02/08/2024 | RxSight Inc | RXSIGHT CONTACT LENS (Device), RXSIGHT INJECTOR CARTRIDGE, RXSIGHT INJECTOR HANDPIECE | Food and Beverage | In-kind items and services | $116.97 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/04/2023 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $20.01 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/08/2023 | ABBVIE INC. | LUMIGAN (Drug), ALPHAGAN P | Food and Beverage | In-kind items and services | $14.74 | General |
| Category: EYE CARE | ||||||
| 07/21/2023 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | Cash or cash equivalent | $18.15 | General |
| Category: Ophthalmology | ||||||
| 03/14/2023 | Bausch & Lomb Americas Inc. | VYZULTA (Drug) | Food and Beverage | In-kind items and services | $19.13 | General |
| Category: Ophthalmology | ||||||
| 03/06/2023 | Novartis Pharmaceuticals Corporation | XIIDRA (Drug) | Food and Beverage | In-kind items and services | $21.41 | General |
| Category: Ophthalmology | ||||||
| 12/16/2022 | ABBVIE INC. | LUMIGAN (Drug) | Food and Beverage | In-kind items and services | $18.15 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/02/2022 | ABBVIE INC. | DURYSTA (Drug) | Food and Beverage | In-kind items and services | $19.80 | General |
| Category: GLAUCOMA | ||||||
| 09/26/2022 | ABBVIE INC. | DURYSTA (Drug) | Food and Beverage | In-kind items and services | $96.99 | General |
| Category: GLAUCOMA | ||||||
| 09/21/2021 | Bausch & Lomb, a division of Bausch Health US, LLC | VYZULTA (Drug) | Food and Beverage | In-kind items and services | $101.87 | General |
| Category: Ophthalmology | ||||||
| 08/05/2021 | Kala Pharmaceuticals, Inc. | INVELTYS (Drug), EYSUVIS | Food and Beverage | In-kind items and services | $11.39 | General |
| Category: Ocular | ||||||
| 07/15/2021 | Allergan, Inc. | RESTASIS MULTIDOSE (Drug) | Food and Beverage | In-kind items and services | $13.66 | General |
| Category: DRY EYE | ||||||
| 03/15/2021 | Allergan, Inc. | LUMIGAN (Drug) | Food and Beverage | In-kind items and services | $20.97 | General |
| Category: OPHTHALMOLOGY | ||||||
| 02/05/2021 | NOVARTIS PHARMACEUTICALS CORPORATION | XIIDRA (Drug) | Food and Beverage | In-kind items and services | $13.74 | General |
| Category: OPHTHALMOLOGY | ||||||
| 01/13/2021 | Allergan, Inc. | LUMIGAN (Drug) | Food and Beverage | In-kind items and services | $24.38 | General |
| Category: OPHTHALMOLOGY | ||||||
| 01/07/2021 | Kala Pharmaceuticals, Inc. | INVELTYS (Drug), EYSUVIS | Food and Beverage | In-kind items and services | $18.87 | General |
| Category: Ocular | ||||||
| 12/17/2020 | Novartis Pharmaceuticals Corporation | XIIDRA (Drug) | Food and Beverage | In-kind items and services | $13.69 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/18/2020 | Allergan, Inc. | LUMIGAN (Drug) | Food and Beverage | In-kind items and services | $22.68 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/06/2020 | Allergan, Inc. | RESTASIS (Drug) | Food and Beverage | In-kind items and services | $14.82 | General |
| Category: DRY EYE | ||||||
| 08/12/2020 | Novartis Pharmaceuticals Corporation | XIIDRA (Drug) | Food and Beverage | In-kind items and services | $12.47 | General |
| Category: OPHTHALMOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 1,158 | 1,238 | $191,455 | $75,312 |
| 2022 | 10 | 1,413 | 1,484 | $226,055 | $91,540 |
| 2021 | 10 | 1,544 | 1,621 | $241,025 | $102,719 |
| 2020 | 11 | 1,784 | 1,891 | $266,140 | $114,693 |
Total Patients
5,899
Total Services
6,234
Medicare Billing
$384,264
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 2 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 92250 | Photography of the retina | Office | 2021 | 131 | 133 | $13,300 | $3,727 | 28.0% |
| 92083 | Measurement of field of vision during daylight conditions, extended examination | Office | 2021 | 66 | 67 | $11,390 | $2,793 | 24.5% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 49 | 66 | $3,900 | $2,400 | 61.5% |
| 92134 | Diagnostic imaging of retina | Office | 2021 | 63 | 63 | $6,300 | $1,857 | 29.5% |
| 92002 | Eye and medical examination for diagnosis and treatment, new patient | Office | 2021 | 28 | 28 | $3,500 | $1,303 | 37.2% |
| 76514 | Ultrasound of corneal structure and measurement | Office | 2021 | 31 | 31 | $1,085 | $230.87 | 21.3% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2020 | 721 | 750 | $125,650 | $60,329 | 48.0% |
| 92004 | Eye and medical examination for diagnosis and treatment, new patient, 1 or more visits | Office | 2020 | 190 | 190 | $36,375 | $17,544 | 48.2% |
| 92012 | Eye and medical examination for diagnosis and treatment, established patient | Office | 2020 | 248 | 291 | $40,290 | $16,595 | 41.2% |
| 92250 | Photography of the retina | Office | 2020 | 145 | 146 | $14,600 | $4,691 | 32.1% |
| 92133 | Diagnostic imaging of optic nerve of eye | Office | 2020 | 173 | 173 | $17,300 | $4,669 | 27.0% |
| 92083 | Measurement of field of vision during daylight conditions | Office | 2020 | 84 | 86 | $14,620 | $3,594 | 24.6% |
| 99212 | Established patient office or other outpatient visit, typically 10 minutes | Office | 2020 | 91 | 120 | $6,000 | $3,447 | 57.4% |
| 92134 | Diagnostic imaging of retina | Office | 2020 | 65 | 68 | $6,800 | $1,967 | 28.9% |
| 92002 | Eye and medical examination for diagnosis and treatment, new patient | Office | 2020 | 20 | 20 | $2,275 | $1,089 | 47.8% |
| 99202 | New patient office or other outpatient visit, typically 20 minutes | Office | 2020 | 13 | 13 | $1,040 | $478.71 | 46.0% |
| 76514 | Ultrasound of corneal structure and measurement | Office | 2020 | 34 | 34 | $1,190 | $289.62 | 24.3% |
About Dr. Stephen Hook, M.D
Dr. Stephen Hook, M.D is a Specialist healthcare provider based in Weslaco, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/16/2005. The National Provider Identifier (NPI) number assigned to this provider is 1669454682.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephen Hook, M.D has received a total of $2,912 in payments from pharmaceutical and medical device companies, with $298.86 received in 2024. These payments were reported across 65 transactions from 16 companies. The most common payment nature is "Food and Beverage" ($2,762).
As a Medicare-enrolled provider, Hook has provided services to 5,899 Medicare beneficiaries, totaling 6,234 services with total Medicare billing of $384,264. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Ophthalmology
- Location Weslaco, TX
- Active Since 11/16/2005
- Last Updated 04/06/2017
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1669454682
Products in Payments
- VYZULTA (Drug) $512.98
- Rhopressa (Drug) $238.94
- LUMIGAN (Drug) $197.72
- PROLENSA (Drug) $180.26
- ZYLET (Drug) $172.07
- INVELTYS (Drug) $139.14
- XIIDRA (Drug) $136.22
- DURYSTA (Drug) $135.38
- BESIVANCE (Drug) $123.42
- RXSIGHT CONTACT LENS (Device) $116.97
- RESTASIS (Drug) $115.98
- MIEBO (Drug) $98.81
- LOTEMAX GEL (Drug) $97.07
- LOTEMAX SM (Drug) $95.66
- Prokera (Device) $77.24
- XELPROS (Drug) $23.95
- EYLEA HD (Biological) $20.01
- Syfovre (Drug) $18.15
- TEPEZZA (Biological) $13.83
- RESTASIS MULTIDOSE (Drug) $13.66
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.